Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.

Casey DL, Cheung NV.

Cancer Immunol Res. 2020 Feb;8(2):161-166. doi: 10.1158/2326-6066.CIR-19-0692. Review.

2.

Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group.

Lautz TB, Chi YY, Tian J, Gupta AA, Wolden SL, Routh JC, Casey DL, Dasgupta R, Hawkins DS, Rodeberg DA.

Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32896. [Epub ahead of print]

PMID:
32012255
3.

Clinical Outcomes of Recurrent Intracranial Meningiomas Treated with Proton Beam Reirradiation.

Imber BS, Neal B, Casey DL, Darwish H, Lin AL, Cahlon O, Chon B, Tsai H, Hug E, Yamada Y, Yang TJ.

Int J Part Ther. 2019 Spring;5(4):11-22. doi: 10.14338/IJPT-18-00045.1. Epub 2019 May 1.

4.

Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.

Casey DL, Wexler LH, Pitter KL, Samstein RM, Slotkin EK, Wolden SL.

Clin Cancer Res. 2019 Nov 7. doi: 10.1158/1078-0432.CCR-19-2631. [Epub ahead of print]

PMID:
31699828
5.

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma.

Casey DL, Lin TY, Cheung NV.

Front Oncol. 2019 Jun 19;9:537. doi: 10.3389/fonc.2019.00537. eCollection 2019. Review.

6.

Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.

Casey DL, Chi YY, Donaldson SS, Hawkins DS, Tian J, Arndt CA, Rodeberg DA, Routh JC, Lautz TB, Gupta AA, Yock TI, Wolden SL.

Cancer. 2019 Sep 15;125(18):3242-3248. doi: 10.1002/cncr.32204. Epub 2019 Jun 7.

PMID:
31174239
7.

High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases.

Casey DL, Pitter KL, Imber BS, Lin A, Chan TA, Beal K, Yamada Y, Feldman DR, Yang TJ.

J Neurooncol. 2019 May;142(3):523-528. doi: 10.1007/s11060-019-03123-0. Epub 2019 Feb 15.

PMID:
30771201
8.

Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.

Casey DL, Kushner BH, Cheung NV, Modak S, Basu EM, Roberts SS, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):409-414. doi: 10.1016/j.ijrobp.2019.02.004. Epub 2019 Feb 11.

PMID:
30763661
9.

Femoral Fracture in Primary Soft-Tissue Sarcoma of the Thigh and Groin Treated with Intensity-Modulated Radiation Therapy: Observed versus Expected Risk.

Folkert MR, Casey DL, Berry SL, Crago A, Fabbri N, Singer S, Alektiar KM.

Ann Surg Oncol. 2019 May;26(5):1326-1331. doi: 10.1245/s10434-019-07182-5. Epub 2019 Jan 31.

PMID:
30706225
10.

Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.

Casey DL, Wexler LH, Wolden SL.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1151-1157. doi: 10.1016/j.ijrobp.2018.11.049. Epub 2018 Nov 30. Erratum in: Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):223.

PMID:
30508617
11.

Dose-escalation is needed for gross disease in high-risk neuroblastoma.

Casey DL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL.

Pediatr Blood Cancer. 2018 Jul;65(7):e27009. doi: 10.1002/pbc.27009. Epub 2018 Feb 22.

12.

Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

Casey DL, Pitter KL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1204-1209. doi: 10.1016/j.ijrobp.2018.01.008. Epub 2018 Jan 9.

13.

Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach.

Casey DL, Wolden SL.

J Neurol Surg B Skull Base. 2018 Feb;79(1):58-64. doi: 10.1055/s-0037-1617450. Epub 2018 Jan 18. Review.

14.

Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy.

Beckham TH, Casey DL, LaQuaglia MP, Kushner BH, Modak S, Wolden SL.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):486-493. doi: 10.1016/j.ijrobp.2017.04.003. Epub 2017 Apr 11.

15.

Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.

Casey DL, Kushner BH, Cheung NK, Modak S, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):393-400. doi: 10.1016/j.ijrobp.2016.05.020. Epub 2016 May 27.

16.

Late Toxicities of Intensity-Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma.

Lockney NA, Friedman DN, Wexler LH, Sklar CA, Casey DL, Wolden SL.

Pediatr Blood Cancer. 2016 Sep;63(9):1608-14. doi: 10.1002/pbc.26061. Epub 2016 May 16.

17.

Extraskeletal osteosarcoma of the hand: the role of marginal excision and adjuvant radiation therapy.

Casey DL, van de Rijn M, Riley G, Tung KW, Mohler DG, Donaldson SS.

Hand (N Y). 2015 Dec;10(4):602-6. doi: 10.1007/s11552-015-9760-0. Epub 2015 Apr 17. Review.

18.

Second cancer risk in childhood cancer survivors treated with intensity-modulated radiation therapy (IMRT).

Casey DL, Friedman DN, Moskowitz CS, Hilden PD, Sklar CA, Wexler LH, Wolden SL.

Pediatr Blood Cancer. 2015 Feb;62(2):311-316. doi: 10.1002/pbc.25285. Epub 2014 Oct 18.

PMID:
25328040
19.

Ewing sarcoma in adults treated with modern radiotherapy techniques.

Casey DL, Meyers PA, Alektiar KM, Magnan H, Healey JH, Boland PJ, Wolden SL.

Radiother Oncol. 2014 Nov;113(2):248-53. doi: 10.1016/j.radonc.2014.11.023. Epub 2014 Nov 26.

PMID:
25613397
20.

Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography.

Casey DL, Wexler LH, Fox JJ, Dharmarajan KV, Schoder H, Price AN, Wolden SL.

Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1136-42. doi: 10.1016/j.ijrobp.2014.08.005.

PMID:
25539372
21.

Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma.

Casey DL, Wexler LH, Meyers PA, Magnan H, Chou AJ, Wolden SL.

Pediatr Blood Cancer. 2015 Mar;62(3):445-9. doi: 10.1002/pbc.25294. Epub 2014 Oct 24.

22.

Whole lung irradiation for adults with pulmonary metastases from Ewing sarcoma.

Casey DL, Alektiar KM, Gerber NK, Wolden SL.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1069-1075. doi: 10.1016/j.ijrobp.2014.04.036. Epub 2014 Jul 8.

PMID:
25035210
23.

Favorable outcomes after whole abdominopelvic radiation therapy for pediatric and young adult sarcoma.

Casey DL, Wexler LH, LaQuaglia MP, Meyers PA, Wolden SL.

Pediatr Blood Cancer. 2014 Sep;61(9):1565-9. doi: 10.1002/pbc.25088. Epub 2014 May 4.

PMID:
24798662
24.

Patterns of failure for rhabdomyosarcoma of the perineal and perianal region.

Casey DL, Wexler LH, LaQuaglia MP, Meyers PA, Wolden SL.

Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):82-7. doi: 10.1016/j.ijrobp.2014.01.051.

PMID:
24725692
25.

Positive organizational outcomes associated with a penchant for openness.

McMillan GS, Casey DL.

Sci Eng Ethics. 2013 Sep;19(3):799-812. doi: 10.1007/s11948-012-9404-5. Epub 2012 Oct 13.

PMID:
23065540
26.

Acetaminophen toxicity in an urban county hospital.

SchiĆødt FV, Rochling FA, Casey DL, Lee WM.

N Engl J Med. 1997 Oct 16;337(16):1112-7.

27.
28.

Minocycline treatment for leukocytoclastic vasculitis associated with rheumatoid arthritis.

Houck HE, Kauffman CL, Casey DL.

Arch Dermatol. 1997 Jan;133(1):15-6. No abstract available.

PMID:
9006367
29.

Myotonic protein kinase expression in human and bovine lenses.

Dunne PW, Ma L, Casey DL, Epstein HF.

Biochem Biophys Res Commun. 1996 Aug 5;225(1):281-8.

PMID:
8769131
30.

Localization of myotonic dystrophy protein kinase in skeletal muscle and its alteration with disease.

Dunne PW, Ma L, Casey DL, Harati Y, Epstein HF.

Cell Motil Cytoskeleton. 1996;33(1):52-63.

PMID:
8824734
31.

Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia.

Karlsberg PL, Lee WM, Casey DL, Cockerell CJ, Cruz PD Jr.

Arch Dermatol. 1995 Oct;131(10):1119-23.

PMID:
7574826
33.

Human cardiac and skeletal muscle spectrins: differential expression and localization.

Vybiral T, Winkelmann JC, Roberts R, Joe E, Casey DL, Williams JK, Epstein HF.

Cell Motil Cytoskeleton. 1992;21(4):293-304.

PMID:
1628325
34.
35.

Kinetics and mechanism of the hydrolysis of a 2-substituted imidazoline, cibenzoline (cifenline).

Ross AJ, Go MV, Casey DL, Palling DJ.

J Pharm Sci. 1987 Apr;76(4):306-9.

PMID:
3598889
36.

Analysis of carprofen dosage forms and drug substance by high-performance liquid chromatography.

Ross AJ, Del Mauro MD, Sokoloff HK, Casey DL.

J Pharm Sci. 1984 Sep;73(9):1211-5.

PMID:
6491938
37.

Preparation and preliminary tissue studies of optically active 11 C-D- and L-phenylalanine.

Casey DL, Digenis GA, Wesner DA, Washburn LC, Chaney JE, Hayes RL, Callahan AP.

Int J Appl Radiat Isot. 1981 May;32(5):325-30. No abstract available.

PMID:
7251209
38.

Method for monitoring hard gelatin capsule disintegration times in humans using external scintigraphy.

Casey DL, Beihn RM, Digenis GA, Shabhu MB.

J Pharm Sci. 1976 Sep;65(9):1412-3. No abstract available.

PMID:
966168

Supplemental Content

Loading ...
Support Center